In patients with moderate hepatic impairment, clearance of unbound tiagabine is reduced by about 60%. These patients may require reduced initial and maintenance doses of tiagabine or longer dosing intervals compared patients with normal hepatic function.
Pediatric. Tiagabine has not been investigated in adequate and well-controlled clinical trials in patients below the age of 12 years.
Geriatric. The pharmacokinetic profile of tiagabine is similar in healthy elderly and healthy young adults.
Pregnancy. Because teratogenic effects were seen in the offspring of rats exposed to maternally toxic doses of tiagabine, and because experience in humans is limited, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy. Because of the possibility that tiagabine may be excreted in breast milk, patients should be advised to exercise caution in breast feeding.
Anesthesia. No adverse interaction with anesthetic agents have been reported.